All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC

August 10th 2023

David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.

Lack of Clinical Benefit Leads to End of Development for Etrumadenant in mCRPC

August 10th 2023

The development of etrumadenant as a potential treatment option for patients with metastatic castration-resistant prostate cancer will be discontinued after data from the phase 1/2 ARC-6 trial did not demonstrate a sufficient clinical benefit for etrumadenant plus zimberelimab and docetaxel compared with docetaxel alone.

FDA Approves Talquetamab for Relapsed/Refractory Multiple Myeloma

August 10th 2023

The FDA has granted accelerated approval to talquetamab-tgvs for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

FDA Issues CRL to NDA for Avasopasem in Radiotherapy-Induced Severe Oral Mucositis in Head and Neck Cancer

August 9th 2023

The FDA has issued a complete response letter to the new drug application seeking the approval of avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment.

Dostarlimab/Chemo Approval Changes Treatment Paradigm for dMMR/MSI-H Advanced or Recurrent Endometrial Cancer

August 9th 2023

Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.

Real-World Data Support Role of Palbociclib in HR+/HER2– Metastatic Breast Cancer

August 9th 2023

Bhuvaneswari Ramaswamy, MD, and colleagues highlight treatment for patients with HR-positive breast cancer, discuss the role of pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer, and expand on unmet needs for patients with metastatic HER2-positive breast cancer.

FDA Grants Regular Approval to Pralsetinib for Metastatic RET Fusion+ NSCLC

August 9th 2023

The FDA has granted regular approval to pralsetinib (Gavreto) for adult patients with metastatic RET fusion–positive non–small cell lung cancer, as detected by an FDA-approved test.

Novel PROTACs Broaden the HR+ Breast Cancer Investigational Landscape

August 9th 2023

Seth Wander, MD, PhD, discusses evidence to support the investigation of PROTACs in patients with hormone receptor–positive breast cancer; preliminary efficacy and safety findings with vepdegestrant; and potential strategies for targeting acquired ESR1 resistance mutations.

City of Hope Ranks Among Nation’s Top 10 Best Hospitals for Cancer

August 9th 2023

The ranking by U.S. News & World Report marks the latest recognition for the organization as one of the nation’s elite cancer hospitals.

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9th 2023

Treatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data from the dose-escalation portion of the phase 1/2 ABILITY-1 trial.

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

August 9th 2023

Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

August 9th 2023

The PD-1 inhibitor pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes.

Experts Provide Key Perspectives on the US Cisplatin/Carboplatin Shortage

August 8th 2023

Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.

Expanding Breast Cancer Armamentarium Is Increasing the Quality of Individualized Care

August 8th 2023

Michelina Cairo, MD, discusses key insights from trials including SONIA and CAPItello-291; how adverse effects inform treatment decisions across the breast cancer spectrum; and where the future is headed for ADCs and oral SERDs in patients with breast cancer.

Cisplatin/Carboplatin Shortages Underscore Need for Strategies to Prevent Future Cancer Drug Disruptions

August 8th 2023

Balazs Halmos, MD, explains why a national effort is needed to mitigate current and future drug shortages in oncology and discusses strategies being used to navigate the current cisplatin and carboplatin shortages.

Camsirubicin Reduces Tumor Size in Advanced Soft Tissue Sarcoma

August 8th 2023

Treatment with camsirubicin led to a reduction in tumor size in patients with advanced soft tissue sarcoma.

FDA Awards Orphan Drug Designation to LSTA1 for Malignant Glioma

August 8th 2023

The FDA has granted orphan drug designation to LSTA1 for use as a potential therapeutic option in patients with malignant glioma, according to an announcement from Lisata Therapeutics, Inc.

University of Chicago Medical Center Ranks Among Nation’s Best in 10 Specialties, According to U.S. News Survey

August 8th 2023

The University of Chicago Medical Center ranks among the nation’s best hospitals in 10 specialties, according to results of the U.S. News & World Report’s annual survey.

FDA Green Lights Companion Diagnostic for Avapritinib in Gastrointestinal Stromal Tumors

August 8th 2023

The FDA has approved the therascreen PDGFRA RGQ PCR kit for use as a companion diagnostic, co-developed by Qiagen and Blueprint Medicines, to assist in the identification of patients with gastrointestinal stromal tumors who may be candidates to receive avapritinib.

PROs Represent a Vital Aspect in Design of GI Cancer Clinical Trials

August 8th 2023

Pamela Kunz, MD, details key clinical trial updates across the gastrointestinal cancer arena presented during the 2023 ASCO Annual Meeting, including the phase 3 PROSPECT trial in locally advanced rectal cancer and the phase 3 IMbrave050 trial in patients with resected in hepatocellular carcinoma at high risk of recurrence.